Close Menu

sepsis

The firm noted that its study showed strong performance data, including high sensitivity and high specificity, in providing results direct from blood.

GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.

Its product revenues were up 30 percent year over year, but research revenues decreased 89 percent. The firm posted $329,000 in grant contribution revenues.

The company has split bloodstream infection testing into three multiplex panels that can detect a total of 56 pathogen targets and 10 markers of antimicrobial resistance.

The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.

A display at a booth at ECCMID where antimicrobial resistance was a major theme.

Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.

The firm said that its new hematology-based cellular biomarker test has the potential to advance clinicians’ approach to sepsis triage and diagnosis.

The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.

Immunexpress received US clearance for a direct-from-blood sepsis test in 2017 and recently won a contract to commercialize a sample-to-answer sepsis assay.

Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.

Pages